Tokyo, Japan. July 20, 2022



ThinkCyte Inc., a biotechnology company pioneering novel cell analysis and sorting instruments, announced today the launch of their Premier Early Access Program and recruitment of participation from key biopharmaceutical industry partners and leading academic centers. The program will give a select group of innovation-minded life science organizations from across the globe advanced access to ThinkCyte’s new label-free platform for cell analysis and sorting. Through a combination of proprietary optical signals and artificial intelligence, the system provides researchers with an entirely new data readout of ‘single-cell fingerprints’ and enables the isolation of target cells, untouched by external labels, for downstream research and development.



“We have seen tremendous excitement and interest in the early access program for the new system, which lets scientists reach deeper insights into cellular phenotypes and enables isolation of precious target cells truly untouched,” said Janette Phi, Chief Business Officer of ThinkCyte. “Currently, the ability to isolate cells with specific functional characteristics is limited to invasive technologies that can alter cellular states. Our new system not only allows scientists to sort cells by traditional fluorescence markers, but also unlocks the critical ability to perform truly label-free cell analysis and sorting. This is a new chapter in the way cellular therapy, tumor profiling, and genomics R&amp;D will be done and we look forward to having our premier early access partners join us on this journey.”&nbsp;



The system will provide researchers with a powerful tool to study solid tumor and hematological cancers, isolate live cells with defined phenotypes such as non-exhausted or activated T-cells, and characterize subtle phenotypes that aren’t detectable by current approaches. Through the premier early access program, the company will accelerate innovative R&amp;D programs by working with select biopharmaceutical companies and key academic and clinical centers of excellence to develop custom, partner-specific applications prior to the full commercial launch of the system in early 2023. To learn more about the Premier Early Access Program or other partnering opportunities at ThinkCyte, <a href="mailto:contact@wp.thinkcyte.com">contact@wp.thinkcyte.com</a>.&nbsp;



For job opportunities at ThinkCyte, explore our careers page at <a href="http://wp.thinkcyte.com/careers/">http://wp.thinkcyte.com/careers/</a>.&nbsp;



About ThinkCyte Inc.



ThinkCyte, founded in 2016 with offices in Tokyo, Japan and San Carlos, California is a biotechnology company that develops innovative instruments based on integrated, multidisciplinary technologies to enable life science research, diagnostics, and therapeutic development. The company pioneered Ghost Cytometry, a proprietary AI-based, label-free cell sorting technology with partners in major global biopharmaceutical companies and leading academic research institutes to drive pioneering research. <a href="http://wp.thinkcyte.com">www.thinkcyte.com</a>.

ThinkCyte announces Premier Early Access Program for its new label-free cell characterization and sorting system

Tokyo, Japan. July 11, 2022



ThinkCyte Inc., a biotechnology company pioneering novel cell analysis and sorting instruments, announced today that applications of its Ghost Cytometry technology were presented at several leading industry meetings. In May, the company was selected to present applications of the platform to experts in drug discovery at the prestigious Keystone Symposia. The company was also selected to deliver a podium presentation at the 2022 International Association for the Advancement of Cytometry’s (CYTO) annual meeting, sharing applications in clinical medicine and cellular therapy with a talk entitled ‘Machine vision-based label-free cell analysis and sorting for clinical diagnosis and cell therapy.’ The company and its Ghost Cytometry platform were also selected as one of three finalists for the Technology Showcase at CYTO, which highlights innovative and disruptive cytometric technologies.



“We are incredibly pleased to be able to share our most recent work using Ghost Cytometry with the broader scientific community.” said ThinkCyte’s CEO Waichiro Katsuda. “It’s an exciting time to be in the field of drug and cellular therapy with innovative approaches being developed to extract novel information from cells. We look forward to showcasing more of our internal work and collaborations with existing partners in the months ahead.”



Ghost Cytometry is a novel flow-cytometry based platform for cell analysis and sorting. Using a combination of proprietary optical designs and artificial intelligence, Ghost Cytometry provides researchers with an entirely new data lens for capturing complex single-cell phenotypes into a “cellular fingerprint” and enables the isolation of live target cells, untouched by external labels, for downstream research and development applications.



To learn more about partnering opportunities with ThinkCyte, <a href="http://wp.thinkcyte.com/contact/">contact ThinkCyte here</a>. For information about job opportunities at ThinkCyte, explore our careers page at <a href="http://wp.thinkcyte.com/careers/">http://wp.thinkcyte.com/careers/</a>. 



About ThinkCyte Inc.



ThinkCyte, founded in 2016 with offices in Tokyo, Japan and San Carlos, California is a biotechnology company that develops innovative instruments based on integrated, multidisciplinary technologies to enable life science research, diagnostics, and therapeutic development. The company pioneered Ghost Cytometry, a proprietary AI-based, label-free cell sorting technology and works with major global biopharmaceutical companies and leading academic research institutes to further drive pioneering research. For more information, please visit <a href="http://wp.thinkcyte.com">www.thinkcyte.com</a>.

ThinkCyte shares applications of Ghost Cytometry with industrial and academic thought leaders

ThinkCyte Inc., a biotechnology company pioneering Ghost Cytometry, a proprietary AI-based, label-free cell sorting technology, today announced the establishment of their new US office in the San Francisco Bay Area and the appointment of Janette Phi as Chief Business Officer (CBO). Both are major milestones in the company's continued global expansion and growth. Hikaru Nagahori, previous CBO, is appointed as Chief Operating Officer (COO) and President of the US office.



The new location in San Carlos, CA is the company's first office outside of its Tokyo headquarters and will be home to a growing team of biologists, data scientists, and commercial executives. Following recent announcements of <a href="http://wp.thinkcyte.com/news/20210512-en/">strategic partnerships</a> with leading scientific instrument manufacturers and the successful closing of $26M in <a href="http://wp.thinkcyte.com/news/20210519-en/">Series B funding</a>, the establishment of a US-base of operations is a significant step in the company's plans to commercialize ThinkCyte's technology. ThinkCyte's platform, originally described in Science, enables researchers to isolate specific cell populations of interest, untouched by external molecular labels, for downstream R&amp;D applications.



"We are very excited to announce these major achievements in the company's continued growth," said ThinkCyte's CEO Waichiro Katsuda. "The San Francisco Bay Area has a storied history for bringing new life science technologies to market and we couldn't imagine a better place to continue our engagements with innovation-minded partners. We are also extraordinarily fortunate to bring someone of Janette Phi's caliber and experience to ThinkCyte. She is a recognized industry leader with a proven track record of guiding innovative scientific instrumentation companies through the pivotal stages of their commercial evolution."



Ms. Phi brings over 30 years of business experience with advanced scientific technology companies. She has served as CBO for IntelliCyt, COO for Xcell Biosciences and CCO for Applied Cells and ONI. She holds a B.S. in Cell Biology from the University of California, Berkeley and an MBA with an emphasis in Marketing &amp; Finance from Santa Clara University.



Commenting on her appointment, Ms. Phi said, "Throughout my career, I've been exposed to many novel technologies, but ThinkCyte's approach is truly revolutionary. I am thrilled to join a purpose-driven company providing an entirely new way of looking at biology. The impact on disease diagnosis and drug development will drive better clinical, operational, and research outcomes for biopharmaceutical organizations of all sizes."



To learn more about partnering opportunities with ThinkCyte, <a href="http://wp.thinkcyte.com/contact/">contact here</a>. For information about job opportunities at ThinkCyte, explore <a href="https://jobs.lever.co/thinkcyte">our careers page</a>.







About ThinkCyte Inc. ThinkCyte, founded in 2016 and headquartered in Tokyo, Japan, is a biotechnology company that develops innovative instruments based on integrated, multidisciplinary technologies to enable life science research, diagnostics, and therapeutic development. The company pioneered Ghost Cytometry, a proprietary AI-based, label-free cell sorting technology and works with major global biopharmaceutical companies and leading academic research institutes to further drive pioneering research. The company was selected for the prestigious J-Startup program by the Ministry of Economy, Trade and Industry of Japan and has graduated from the Berkeley SkyDeck Startup Accelerator program. Visit <a href="http://wp.thinkcyte.com/">www.thinkcyte.com</a>.

Deeper insights,
better treatments
— a single cell at a time

Machine
Vision-based
Cell Sorting

Platform

Contact

News

We Are Hiring

Deeper insights, better treatments — a single cell at a time